Evidence map›Paper›PMID 21248708›Full record

ArticleJournal of visualized experiments : JoVE2011

The production of C. elegans transgenes via recombineering with the galK selectable marker.

Yue Zhang, Luv Kashyap, Annabel A Ferguson, Alfred L Fisher

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yue ZhangDepartment of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA. yzhang1@bidmc.harvard.edu
Luv Kashyap
Annabel A Ferguson
Alfred L Fisher
University of Pittsburgh · USBeth Israel Deaconess Medical Center · US

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
Regulation on of the AIRAP/aip-1 pathway by metabolic stressR01ES017761 · NIEHS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FISHER, ALFRED L · 2010 to 2014
$1.1M
Dopamine, Tryosine, and their Metabolites in Aging in Neurodegenerative DiseaseK08AG028977 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FISHER, ALFRED L · 2006 to 2009
$756k
Identification of Genetic Modifiers of Sarcopenia in C. elegansR21AG029870 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FISHER, ALFRED L · 2008 to 2009
$270k
NIA NIH HHS AG024827NIA NIH HHS AG028977NIA NIH HHS K08 AG028977NIA NIH HHS P30 AG024827NIA NIH HHS R21 AG029870NIEHS NIH HHS R01 ES017761
6 · The paper itself

Abstract

The creation of transgenic animals is widely utilized in C. elegans research including the use of GFP fusion proteins to study the regulation and expression pattern of genes of interest or generation of tandem affinity purification (TAP) tagged versions of specific genes to facilitate their purification. Typically transgenes are generated by placing a promoter upstream of a GFP reporter gene or cDNA of interest, and this often produces a representative expression pattern. However, critical elements of gene regulation, such as control elements in the 3' untranslated region or alternative promoters, could be missed by this approach. Further only a single splice variant can be usually studied by this means. In contrast, the use of worm genomic DNA carried by fosmid DNA clones likely includes most if not all elements involved in gene regulation in vivo which permits the greater ability to capture the genuine expression pattern and timing. To facilitate the generation of transgenes using fosmid DNA, we describe an E. coli based recombineering procedure to insert GFP, a TAP-tag, or other sequences of interest into any location in the gene. The procedure uses the galK gene as the selection marker for both the positive and negative selection steps in recombineering which results in obtaining the desired modification with high efficiency. Further, plasmids containing the galK gene flanked by homology arms to commonly used GFP and TAP fusion genes are available which reduce the cost of oligos by 50% when generating a GFP or TAP fusion protein. These plasmids use the R6K replication origin which precludes the need for extensive PCR product purification. Finally, we also demonstrate a technique to integrate the unc-119 marker on to the fosmid backbone which allows the fosmid to be directly injected or bombarded into worms to generate transgenic animals. This video demonstrates the procedures involved in generating a transgene via recombineering using this method.

Indexed as

Animals, Genetically ModifiedTransgenesAnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsGalactokinaseGenetic EngineeringGenetic MarkersRecombinant Fusion ProteinsRecombination, GeneticCaenorhabditis elegans ProteinsGalactokinaseGenetic MarkersRecombinant Fusion Proteins

Identifiers

PMID21248708
PMCPMC3182660
OpenAlexW2029498223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.